EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin) (Q79832284)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17323056%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

title

EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17323056%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17323056%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Wim Oyen

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17323056%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

Jan Tennvall

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17323056%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Manfred Fischer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17323056%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Angelika Bischof Delaloye

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17323056%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Emilio Bombardieri

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17323056%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Lisa Bodei

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17323056%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Francesco Giammarile

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17323056%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Boudewijn Brans

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17323056%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Therapy Committee, EANM

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17323056%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Oncology Committee, EANM

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17323056%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Dosimetry Committee, EANM

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17323056%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

publication date

1 April 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17323056%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Nuclear Medicine and Molecular Imaging

26 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17323056%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17323056%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

616-622

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17323056%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17323056%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00259-007-0372-y

26 December 2019

exact match

0 references

cites work

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma

1 reference

12 December 2020

Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma

1 reference

12 December 2020

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

12 December 2020

Immunotherapy of Non-Hodgkin's lymphomas.

1 reference

12 December 2020

Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice

1 reference

12 December 2020

[Guideline for radioimmunotherapy of rituximab relapsed or refractory CD20(+) follicular B-cell non-Hodgkin's lymphoma]

1 reference

12 December 2020

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

12 December 2020

Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials

1 reference

12 December 2020

Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma

1 reference

12 December 2020

[Radioimmunoconjugates: therapy of non-Hodgkin lymphomas and colorectal carcinomas]

1 reference

12 December 2020

Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.

1 reference

12 December 2020

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

12 December 2020

Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma.

1 reference

12 December 2020

Advancing role of radiolabeled antibodies in the therapy of cancer

1 reference

12 December 2020

Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma

1 reference

12 December 2020

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

12 December 2020

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

1 reference

12 December 2020

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

1 reference

12 December 2020

10.1007/S00259-007-0372-Y

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17323056%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference